Replimune Group (REPL) Q1 2027 earnings summary

Executive summary

• Achieved FDA accelerated approval for TUDRIQEV (vusolimogene oderparepvec-wtpg) in combination with nivolumab for unresectable advanced cutaneous melanoma in August 2026, initiating commercial launch within 60 days and marking a major milestone.

• IGNYTE trial data showed an objective response rate of 24.2% and median duration of response of 14.1 months in efficacy-evaluable population; safety profile was predominantly mild to moderate.

• Enrollment continues in the IGNYTE-3 confirmatory Phase 3 trial, a postmarketing requirement, and in the REVEAL study for RP2 in metastatic uveal melanoma, with Phase 2/3 transition expected in Q1 2027.

• Company restructured in April 2026, reducing workforce by 55% and decreasing operating expenses.

• Michelle DiNapoli appointed Chief Commercial Officer, bringing extensive oncology commercialization experience.

Financial highlights

• Net loss for the quarter ended June 30, 2026 was $69.8 million, an improvement from $86.7 million in the prior year quarter.

• Research and development expenses decreased to $49.3 million from $57.8 million year-over-year, driven by lower personnel and study costs.

• Selling, general and administrative expenses fell to $19.0 million from $32.6 million, reflecting restructuring and reduced commercial team.

• Cash and cash equivalents and short-term investments totaled $195.3 million as of June 30, 2026, down from $268.9 million at March 31, 2026.

• Net loss per share (basic and diluted) was $0.72 for the quarter, compared to $0.95 in the prior year quarter.

Outlook and guidance

• Cash runway expected to fund operations for more than twelve months from the financial statement issuance, including commercialization of TUDRIQEV and ongoing clinical trials, supported by $141 million net proceeds from August 2026 equity raise.

• Focus remains on successful commercial launch of TUDRIQEV, completion of confirmatory IGNYTE-3 trial (primary endpoint readout expected in 2030), and advancing RP2 and RP3 programs.

• Expenses anticipated to increase with commercialization and continued clinical development, but offset by restructuring savings.